دورية أكاديمية
أعرض في EDS

TRMT10C-mediated m7G modification of circFAM126A inhibits lung cancer growth by regulating cellular glycolysis.

التفاصيل البيبلوغرافية
العنوان: TRMT10C-mediated m7G modification of circFAM126A inhibits lung cancer growth by regulating cellular glycolysis.
المؤلفون: Zhao Q; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Li X; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Wu J; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Zhang R; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Chen S; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Cai D; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Xu H; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Peng W; School of Public Health, Guangxi Medical University, Nanning, 530021, China.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China., Li G; School of Public Health, Guangxi Medical University, Nanning, 530021, China. ligang@gxmu.edu.cn.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China. ligang@gxmu.edu.cn., Nan A; School of Public Health, Guangxi Medical University, Nanning, 530021, China. nanaruo@163.com.; Guangxi Key Laboratory of Environment and Health Research, Guangxi Medical University, Nanning, 530021, China. nanaruo@163.com.
المصدر: Cell biology and toxicology [Cell Biol Toxicol] 2024 Sep 18; Vol. 40 (1), pp. 78. Date of Electronic Publication: 2024 Sep 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Switzerland NLM ID: 8506639 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-6822 (Electronic) Linking ISSN: 07422091 NLM ISO Abbreviation: Cell Biol Toxicol Subsets: MEDLINE
أسماء مطبوعة: Publication: [Cham] : Springer
Original Publication: Princeton, N.J. : Princeton Scientific Publishers, c1984-
مواضيع طبية MeSH: Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , RNA, Circular*/genetics , RNA, Circular*/metabolism , Glycolysis*/genetics , Methyltransferases*/metabolism , Methyltransferases*/genetics , Cell Proliferation*/genetics, Humans ; Animals ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Mice, Nude ; Mice ; Proto-Oncogene Proteins c-akt/metabolism ; HSP90 Heat-Shock Proteins/metabolism ; HSP90 Heat-Shock Proteins/genetics ; A549 Cells ; Guanosine/analogs & derivatives ; Guanosine/metabolism ; Male ; Female ; Mice, Inbred BALB C ; Ubiquitination
مستخلص: The N 7 -methylguanosine (m7G) modification and circular RNAs (circRNAs) have been shown to play important roles in the development of lung cancer. However, the m7G modification of circRNAs has not been fully elucidated. This study revealed the presence of the m7G modification in circFAM126A. We propose the novel hypothesis that the methyltransferase TRMT10C mediates the m7G modification of circFAM126A and that the stability of m7G-modified circFAM126A is reduced. circFAM126A is downregulated in lung cancer and significantly inhibits lung cancer growth both in vitro and in vivo. The expression of circFAM126A correlates with the stage of lung cancer and with the tumour diameter, and circFAM126A can be used as a potential molecular target for lung cancer. The molecular mechanism by which circFAM126A increases HSP90 ubiquitination and suppresses AKT1 expression to regulate cellular glycolysis, ultimately inhibiting the progression of lung cancer, is elucidated. This study not only broadens the knowledge regarding the expression and regulatory mode of circRNAs but also provides new insights into the molecular mechanisms that regulate tumour cell metabolism and affect tumour cell fate from an epigenetic perspective. These findings will facilitate the development of new strategies for lung cancer prevention and treatment.
(© 2024. The Author(s).)
References: Mol Cell. 2021 Aug 19;81(16):3339-3355.e8. (PMID: 34352206)
Front Pharmacol. 2022 Jan 14;12:724192. (PMID: 35095481)
Mol Cancer. 2019 Jul 19;18(1):119. (PMID: 31324186)
Am J Hum Genet. 2016 May 5;98(5):993-1000. (PMID: 27132592)
Cell Mol Life Sci. 2019 Nov;76(21):4233-4243. (PMID: 31270581)
Nat Cell Biol. 2015 Apr;17(4):351-9. (PMID: 25774832)
Life Sci. 2020 Aug 15;255:117816. (PMID: 32454155)
DNA Cell Biol. 2020 Oct;39(10):1767-1778. (PMID: 32833542)
EMBO J. 2019 Aug 15;38(16):e100836. (PMID: 31343080)
Nature. 2017 Nov 9;551(7679):251-255. (PMID: 29072297)
Nat Rev Cancer. 2005 Oct;5(10):761-72. (PMID: 16175177)
Cell Death Dis. 2022 May 7;13(5):443. (PMID: 35525866)
Semin Cancer Biol. 2022 Nov;86(Pt 2):334-346. (PMID: 35820598)
Int J Mol Sci. 2023 Jan 30;24(3):. (PMID: 36768924)
Theranostics. 2017 Sep 26;7(17):4183-4191. (PMID: 29158818)
Theranostics. 2020 Jul 9;10(18):8400-8414. (PMID: 32724477)
Cancer Lett. 2021 May 1;505:49-57. (PMID: 33609610)
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
Theranostics. 2022 Oct 31;12(17):7550-7566. (PMID: 36438474)
Biochemistry. 2023 Feb 7;62(3):564-579. (PMID: 36130224)
Nat Rev Mol Cell Biol. 2017 Jun;18(6):345-360. (PMID: 28429788)
Mol Ther. 2021 Dec 1;29(12):3422-3435. (PMID: 34371184)
Nat Commun. 2021 Jan 12;12(1):295. (PMID: 33436560)
Semin Cancer Biol. 2022 Nov;86(Pt 3):1216-1230. (PMID: 36330953)
RNA. 2015 Feb;21(2):180-7. (PMID: 25525153)
J Cell Physiol. 2020 Dec;235(12):9524-9537. (PMID: 32495363)
Nat Rev Drug Discov. 2022 Feb;21(2):141-162. (PMID: 34862480)
Nat Commun. 2019 Oct 16;10(1):4695. (PMID: 31619685)
Nat Rev Clin Oncol. 2023 Sep;20(9):624-639. (PMID: 37479810)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Annu Rev Cell Dev Biol. 2022 Oct 6;38:263-289. (PMID: 35609906)
J Physiol Biochem. 2020 May;76(2):279-290. (PMID: 32100243)
Mol Cell. 2018 Jul 19;71(2):244-255.e5. (PMID: 29983320)
Oncogene. 2018 Feb 1;37(5):555-565. (PMID: 28991235)
Eur J Pharm Biopharm. 2020 Sep;154:317-329. (PMID: 32717390)
J Cell Mol Med. 2019 May;23(5):3711-3723. (PMID: 30920152)
Cell Death Dis. 2020 Jun 8;11(6):437. (PMID: 32513983)
Nucleic Acids Res. 2023 Oct 27;51(19):10536-10550. (PMID: 37779095)
FASEB Bioadv. 2023 Jun 01;5(8):305-320. (PMID: 37554544)
FEBS Open Bio. 2019 Oct;9(10):1726-1733. (PMID: 31376209)
Theranostics. 2020 Feb 10;10(8):3503-3517. (PMID: 32206104)
Nucleic Acids Res. 2016 Sep 19;44(16):7511-26. (PMID: 27317694)
Mol Ther Nucleic Acids. 2020 Nov 17;23:355-368. (PMID: 33425493)
Mol Cancer. 2022 May 6;21(1):109. (PMID: 35524319)
Cell Res. 2017 May;27(5):626-641. (PMID: 28281539)
Mol Cell. 2019 Feb 7;73(3):490-504.e6. (PMID: 30581145)
Lancet. 2018 Mar 17;391(10125):1023-1075. (PMID: 29395269)
Sci Rep. 2023 Sep 7;13(1):14704. (PMID: 37679400)
Mol Cell. 2019 Jun 20;74(6):1278-1290.e9. (PMID: 31031083)
Int J Mol Sci. 2018 Aug 29;19(9):. (PMID: 30158430)
Cancer Res. 2022 Feb 15;82(4):599-614. (PMID: 34916222)
Cell Death Dis. 2020 Dec 2;11(12):1031. (PMID: 33268793)
Cancer Res. 2019 Mar 15;79(6):1019-1031. (PMID: 30808672)
BMC Cancer. 2022 Nov 4;22(1):1132. (PMID: 36333719)
Oncogene. 2010 Feb 11;29(6):930-6. (PMID: 19915615)
Aging (Albany NY). 2022 Jun 29;14(12):5233-5249. (PMID: 35771136)
Int J Mol Sci. 2018 Dec 17;19(12):. (PMID: 30562954)
Annu Rev Biochem. 2017 Jun 20;86:193-224. (PMID: 28460188)
Mol Cell. 2019 Jun 20;74(6):1304-1316.e8. (PMID: 31031084)
RNA Biol. 2017 Mar 4;14(3):361-369. (PMID: 28080204)
Mol Ther Oncolytics. 2022 Aug 23;26:399-412. (PMID: 36159776)
Cancer Res. 2023 Jan 4;83(1):89-102. (PMID: 36102722)
Nat Rev Genet. 2019 Nov;20(11):675-691. (PMID: 31395983)
Cancer Lett. 2017 Oct 10;406:47-53. (PMID: 28797845)
Cell Death Dis. 2019 Nov 25;10(12):885. (PMID: 31767835)
Adv Cancer Res. 2016;129:1-30. (PMID: 26915999)
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10832-7. (PMID: 10995457)
Nat Rev Genet. 2023 Mar;24(3):143-160. (PMID: 36261710)
Mol Cancer Ther. 2017 Sep;16(9):1779-1790. (PMID: 28619753)
Pharmacol Res. 2021 Dec;174:105937. (PMID: 34648969)
RNA. 2011 Apr;17(4):718-27. (PMID: 21372189)
Lancet Oncol. 2021 Nov;22(11):e501-e516. (PMID: 34735819)
Clin Transl Med. 2021 Dec;11(12):e675. (PMID: 34936728)
معلومات مُعتمدة: NSFC82260652 National Natural Science Foundation of China; no.AD22080055 Guangxi Science and Technology Base and Talent Special Project
فهرسة مساهمة: Keywords: Glycolysis; HSP90; Lung cancer; circRNA; m7G modification
المشرفين على المادة: 0 (RNA, Circular)
EC 2.1.1.- (Methyltransferases)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
0 (HSP90 Heat-Shock Proteins)
12133JR80S (Guanosine)
تواريخ الأحداث: Date Created: 20240917 Date Completed: 20240917 Latest Revision: 20240920
رمز التحديث: 20240920
مُعرف محوري في PubMed: PMC11408563
DOI: 10.1007/s10565-024-09918-w
PMID: 39289194
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-6822
DOI:10.1007/s10565-024-09918-w